Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

The SMAC Mimetic Lcl-161 Augments the in Vitro and in Vivo anti-Tumor Activity of Rituximab and Chemotherapy in Rituximab Relapse/Refractory Lymphoma Models

Kyle L. Runckel, BS, Joseph Skitzki, MD, Francisco Hernandez, MD, Myron S. Czuczman, MD

Blood (2014) 124 (21): 3110.

https://doi.org/10.1182/blood.V124.21.3110.3110

Published: 2014

Journal Articles

Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, Is Active in Chemotherapy Resistant B-Cell Non-Hodgkin Lymphoma and Enhances the Anti-Tumor Activity of Chemotherapy Agents

Kai Xue, MD, Juan Gu, PhD, Cory Mavis, MSc, Francisco Hernandez, MD, Myron S. Czuczman, MD, Ye Guo, MD

Blood (2014) 124 (21): 5486.

https://doi.org/10.1182/blood.V124.21.5486.5486

Published: 2014

Journal Articles

Up-Regulation of Hexokinase II (HK) Alters the Glucose Metabolism and Disrupts the Mitochondrial Potential in Aggressive B-Cell Lymphoma Contributing to Rituximab-Chemotherapy Resistance and Is a Clinically Relevant Target for Future Therapeutic Development

Juan J Gu, PhD, Anil Singh, MD, Cory Mavis, MSc, Vivek Yanamadala, Kai Xue, MD, Michael Grau, Peter Lenz, Georg Lenz, Myron S. Czuczman, MD, Francisco Hernandez, MD

Blood (2014) 124 (21): 1767.

https://doi.org/10.1182/blood.V124.21.1767.1767

Published: 2014

Journal Articles

Metformin Affects the Proliferation Cell Nuclear Antigen (PCNA) and p21 Protein Interaction Resulting in Direct Anti-Tumor Activity and Enhances the Cytotoxic/Biological Effects of Chemotherapy Agents or Rituximab in Lymphoma in Vitro and in Vivo Pre-Clinical Models

Juan J Gu, PhD, Vivek Yanamadala, Anil Singh, MD, Cory Mavis, MSc, Myron S. Czuczman, MD, Francisco Hernandez, MD

Blood (2014) 124 (21): 1781.

https://doi.org/10.1182/blood.V124.21.1781.1781

Published: 2014

Journal Articles

Altered Glucose Metabolism In Rituximab-Chemotherapy Resistant Cells Is a Potential Target For Future Therapeutic Development

Juan Gu, PhD, Vivek Yanamadala, Cory Mavis, BSc, MSc, Francisco Hernandez, MD, Myron S. Czuczman, MD

Blood (2013) 122 (21): 4413.

https://doi.org/10.1182/blood.V122.21.4413.4413

Published: 2013

Journal Articles

Ixazomib, An Investigational Orally Bioavailable Proteasome Inhibitor, Increases p21 Expression Inducing Caspase-Dependent Cell Death, Cell-Cycle Arrest, and In B-Cell Lymphoma Pre-Clinical Models

Cory Mavis, BSc, MSc, Juan Gu, PhD, Joseph Skitzki, MD, Francisco Hernandez, MD, Myron S. Czuczman, MD

Blood (2013) 122 (21): 1828.

https://doi.org/10.1182/blood.V122.21.1828.1828

Published: 2013

Journal Articles

CBL-C137, a Curaxin and Potent Suppressor Of NF-Kb Activity and Modulator Of p53 Function Is Active In Rituximab-Sensitive Or Resistant Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) Cells

Christopher N. Ibabao, Cory Mavis, BSc, MSc, Jenny Gu, Ph.D, Myron S. Czuczman, MD, Francisco Hernandez, MD

Blood (2013) 122 (21): 1836.

https://doi.org/10.1182/blood.V122.21.1836.1836

Published: 2013

Journal Articles

Downregulation Of Deoxycytidine Kinase In Cytarabine-Resistant Mantle Cell Lymphoma Cells Confers Cross-Resistance To Nucleoside Analogs Fludarabine, Gemcitabine and Cladribine, But Not To Other Classes Of Anti-Lymphoma Agents

Magdalena Klanova, Lucie Lorkova, MSc, Ondrej Vit, MSc, Bokang Maswabi, MD, Jan Molinsky, MD, Jana Pospisilova, MSc, Cory Mavis, BSc, MSc, Francisco Hernandez, MD, Martin Vokurka, MD, PhD, Jiri Petrak, MSc, PhD, Pavel Klener, Jr., MD, PhD

Blood (2013) 122 (21): 3835.

https://doi.org/10.1182/blood.V122.21.3835.3835

Published: 2013

Journal Articles

AMG 319, a Novel Inhibitor of Phosphoinositide-3 Kinase Delta (PI3Kd), Demonstrates Activity in Lymphoma Pre-Clinical Models

Amanda Herko, DO, Cory Mavis, BSc, MSc, Myron S. Czuczman, MD, Francisco Hernandez, MD, PhD

Blood (2012) 120 (21): 3718.

https://doi.org/10.1182/blood.V120.21.3718.3718

Published: 2012

Journal Articles

Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study.

Taimur Sher, MD, Kena C Miller, Sikander Ailawadhi, MD, Debbie Manfredi, Margaret Wood, Wei Tan, Ph.D., Gregory Wilding, Ph.D., Hong Liu, MD, Myron S Czuczman, MD, Francisco Hernandez, MD, Frederick Hong, MD, Raman Sood, MD, Saif Soniwalla, MD, William Lawrence, MD, Peter A. Kouides, MD, Kelvin P. Lee, MD, Asher Chanan-Khan, MD

Blood (2009) 114 (22): 618.

https://doi.org/10.1182/blood.V114.22.618.618

Published: 2009

Journal Articles

Dexamethasone (D), High Dose Ara-C (HA) and Carboplatin (DHAC) with or without Rituximab (R) Is an Effective Salvage Regimen for Patients with Relapsed/Refractory B-Cell Lymphoma in Preparation for Autologous Stem Cell Transplantation.

Raymond Cruz, MD, Myron S. Czuczman, MD, Francisco Hernandez, MD, Ajay Kanra, MD, Swaminathan Padmanabhan, MD

Blood (2006) 108 (11): 4730.

https://doi.org/10.1182/blood.V108.11.4730.4730

Published: 2006

NARROW

The SMAC Mimetic Lcl-161 Augments the in Vitro and in Vivo anti-Tumor Activity of Rituximab and Chemotherapy in Rituximab Relapse/Refractory Lymphoma Models

Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, Is Active in Chemotherapy Resistant B-Cell Non-Hodgkin Lymphoma and Enhances the Anti-Tumor Activity of Chemotherapy Agents

Up-Regulation of Hexokinase II (HK) Alters the Glucose Metabolism and Disrupts the Mitochondrial Potential in Aggressive B-Cell Lymphoma Contributing to Rituximab-Chemotherapy Resistance and Is a Clinically Relevant Target for Future Therapeutic Development

Metformin Affects the Proliferation Cell Nuclear Antigen (PCNA) and p21 Protein Interaction Resulting in Direct Anti-Tumor Activity and Enhances the Cytotoxic/Biological Effects of Chemotherapy Agents or Rituximab in Lymphoma in Vitro and in Vivo Pre-Clinical Models

Altered Glucose Metabolism In Rituximab-Chemotherapy Resistant Cells Is a Potential Target For Future Therapeutic Development

Ixazomib, An Investigational Orally Bioavailable Proteasome Inhibitor, Increases p21 Expression Inducing Caspase-Dependent Cell Death, Cell-Cycle Arrest, and In B-Cell Lymphoma Pre-Clinical Models

CBL-C137, a Curaxin and Potent Suppressor Of NF-Kb Activity and Modulator Of p53 Function Is Active In Rituximab-Sensitive Or Resistant Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) Cells

Downregulation Of Deoxycytidine Kinase In Cytarabine-Resistant Mantle Cell Lymphoma Cells Confers Cross-Resistance To Nucleoside Analogs Fludarabine, Gemcitabine and Cladribine, But Not To Other Classes Of Anti-Lymphoma Agents

AMG 319, a Novel Inhibitor of Phosphoinositide-3 Kinase Delta (PI3Kd), Demonstrates Activity in Lymphoma Pre-Clinical Models

Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study.

Dexamethasone (D), High Dose Ara-C (HA) and Carboplatin (DHAC) with or without Rituximab (R) Is an Effective Salvage Regimen for Patients with Relapsed/Refractory B-Cell Lymphoma in Preparation for Autologous Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only